A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
About this item
Full title
Author / Creator
King, Talmadge E , Bradford, Williamson Z , Castro-Bernardini, Socorro , Fagan, Elizabeth A , Glaspole, Ian , Glassberg, Marilyn K , Gorina, Eduard , Hopkins, Peter M , Kardatzke, David , Lancaster, Lisa , Lederer, David J , Nathan, Steven D , Pereira, Carlos A , Sahn, Steven A , Sussman, Robert , Swigris, Jeffrey J , Noble, Paul W and ASCEND Study Group
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this randomized, controlled trial, the use of pirfenidone in patients with idiopathic pulmonary fibrosis led to a slower rate of loss in forced vital capacity than the use of placebo.
Idiopathic pulmonary fibrosis is a chronic, progressive, and fatal lung disease that is characterized by irreversible loss of lung function.
1
Although pe...
Alternative Titles
Full title
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Authors, Artists and Contributors
Author / Creator
Bradford, Williamson Z
Castro-Bernardini, Socorro
Fagan, Elizabeth A
Glaspole, Ian
Glassberg, Marilyn K
Gorina, Eduard
Hopkins, Peter M
Kardatzke, David
Lancaster, Lisa
Lederer, David J
Nathan, Steven D
Pereira, Carlos A
Sahn, Steven A
Sussman, Robert
Swigris, Jeffrey J
Noble, Paul W
ASCEND Study Group
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1530951292
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1530951292
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1402582
